Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi Sells European Generics Biz | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sanofi Sells European Generics Biz

To focus on core areas of global medicines and emerging markets, specialty care and diabetes and cardiovascular

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi is selling its European generics business to Advent International for approximately €1.9 billion, as part of a continued effort to focus on its core areas of global medicines and emerging markets, specialty care and diabetes and cardiovascular. The deal is expected to close 4Q18 and the new business will be called Zentiva. 

“We believe that Zentiva is a great platform, full of talented people, who we can invest behind to build a new, independent, European generics leader,” commented Advent’s managing directors Tom Allen and Cédric Chateau.

Sanofi’s chief executive officer, Olivier Brandicourt, had planned to sell the business back in 2015 as part of a refocusing effort. Since then, Sanofi also sold its animal health business Merial, purchased Boehringer Ingelheim’s consumer health assets, and acquired Ablynx and Bioverativ.

The company also plans to bolster smaller units: multiple sclerosis, oncology, immunology and consumer healthcare.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters